2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2043

Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Abstract Number: 1943

Adipocytokines in an Osteoarthritis Mouse Model
Abstract Number: 2333

Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Abstract Number: 1443

Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Abstract Number: 1776

Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Abstract Number: 543

Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo
Abstract Number: 2543

Agreement between Paper and Pencil VAS at the Clinic and Electronic VAS at Home in Psoriatic Arthritis and Its Impact on Minimal Disease Activity
Abstract Number: 1390

Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis
Abstract Number: 1177

Airway Findings in Patients with Relapsing Polychondritis
Abstract Number: 894

All Oral Interferon-Free Antivirals for Hepatitis C Virus Cryoglobulinemia Vasculitis: A Long Term Follow up Multicenter International Study
Abstract Number: 183

Allele-Dependent Binding of a Viral Protein to Autoimmune Disease-Associated Genetic Variants
Abstract Number: 2087

Allelic Variants of ABCG2 and Gout Risk
Abstract Number: 1105

Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study
Abstract Number: 2059

Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
Abstract Number: 1121

Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].